Rallybio

The Connecticut-based company launched in 2018, having since built a portfolio of candidates which are in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders.

In December 2022, Rallybio entered into a strategic alliance with Canada’s AbCellera to discover, develop, and commercialize antibody-based therapeutics for rare diseases.

The multi-year, multi-target collaboration will combine AbCellera’s antibody discovery engine with Rallybio’s clinical and commercial expertise in rare diseases to identify optimal clinical candidates and hopefully deliver therapies to patients.

Latest Rallybio News & Features